Mirabegron is a beta-3 adrenergic agonist primarily indicated for the treatment of overactive bladder and neurogenic detrusor overactivity by relaxing the detrusor smooth muscle to increase bladder storage… Read more













![Chemical structure of 2-[[2-2(2-Amino-4-thiazolyl)acetyl]amino]-4-thiazoleacetic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2036283-13-1-2-2-22-Amino-4-thiazolylacetylamino-4-thiazoleacetic-Acid.png&w=3840&q=75)


![Chemical structure of 2-Amino-N-[4-[2-[formyl[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-thiazoleacetamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2865161-72-2-2-Amino-N-4-2-formyl2R-2-hydroxy-2-phenylethylaminoethylphenyl-4-thiazoleacetamide.png&w=3840&q=75)




![Chemical structure of 4-[[2-(2-Amino-4-thiazolyl)acetyl]amino]-benzeneacetic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1365244-64-9-4-2-2-Amino-4-thiazolylacetylamino-benzeneacetic-Acid.png&w=3840&q=75)




























Mirabegron is a beta-3 adrenergic agonist primarily indicated for the treatment of overactive bladder and neurogenic detrusor overactivity by relaxing the detrusor smooth muscle to increase bladder storage capacity. This category provides comprehensive reference standards for the Mirabegron active pharmaceutical ingredient, including its synthetic intermediates, process-related impurities, metabolites, and stable isotope labelled compounds. These materials are essential for pharmaceutical laboratories conducting rigorous quality control, method validation, and impurity profiling to ensure drug safety and regulatory compliance. Stable isotope labelled compounds, in particular, serve as critical internal standards for quantitative bioanalysis, such as LC-MS/MS, allowing for precise identification and quantification of trace components. By utilizing these high-quality reference standards, analytical teams can effectively monitor degradation pathways, characterize process-related contaminants, and maintain the precise standards necessary for development and stability-indicating testing of this therapeutic agent.